Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7253
Reference
MSAN(2021)01
Name
Phyllocontin® (Aminophylline) 225mg and 350mg modified release tablets
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
Phyllocontin® (aminophylline) Continus 225mg and Phyllocontin® Forte Continus 350mg modified-release tablets are being discontinued in the UK. Remaining supplies of the 225mg strength are expected to be exhausted by 30th March 2021 and the 350mg strength are expected to be exhausted by 5th April 2021. Phyllocontin® (aminophylline) is used in adults for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. For children, it is used for the management of asthma. Prescribers will need to review all affected patients and optimise inhaled therapies. Patients who still require a methylxanthine, will need to be switched to theophylline tablets (Uniphyllin Continus®).
Contact Name
Contact Email
Contact Address
Created
2021-02-23 00:00:00
Click to go back to homepage